Advertisement
Singapore markets close in 6 hours 35 minutes

  • Straits Times Index

    3,270.85
    -29.19 (-0.88%)
     

  • Nikkei

    38,446.03
    -389.07 (-1.00%)
     

  • Hang Seng

    18,510.69
    +31.32 (+0.17%)
     

  • FTSE 100

    8,313.67
    +100.18 (+1.22%)
     

  • Bitcoin USD

    62,742.46
    -1,032.20 (-1.62%)
     

  • CMC Crypto 200

    1,299.35
    -65.77 (-4.82%)
     

  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     

  • Dow

    38,884.26
    +31.99 (+0.08%)
     

  • Nasdaq

    16,332.56
    -16.69 (-0.10%)
     

  • Gold

    2,316.30
    -7.90 (-0.34%)
     

  • Crude Oil

    78.06
    -0.32 (-0.41%)
     

  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     

  • FTSE Bursa Malaysia

    1,608.68
    +3.00 (+0.19%)
     

  • Jakarta Composite Index

    7,159.01
    +35.40 (+0.50%)
     

  • PSE Index

    6,588.04
    -30.54 (-0.46%)
     

Invitae Stock: Approach With Caution

Justin Pope, The Motley Fool
·3-min read
Invitae Stock: Approach With Caution

Shares of genetic testing company Invitae (NYSE: NVTA) have surged more than 40% over the past month, a combination of improving investor sentiment toward growth stocks as well as the company's preliminary release of financial results for 2022. Investors need to know about this upcoming event and consider the potential ramifications before buying shares. Earlier this past summer, Invitae's management announced plans to exit non-core businesses to push the company toward positive cash flow.

Continue reading